Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 5/20 | 0.60 |
| ▸ | BCHE | P06276 | 6/20 | 0.54 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19918106 | 1.00 | SNCA (0.60) | SNCABCHEACHEHPGDNOX1 | |
| SCHEMBL14058478 | 0.91 | BCHE (0.64) | SNCABCHEHPGDNOX1NR1H2 | |
| SCHEMBL30858755 | 0.85 | BCHE (0.54) | SNCABCHEACHEHPGDTP53 | |
| SCHEMBL30858752 | 0.85 | BCHE (0.54) | SNCABCHEACHEHPGDTP53 | |
| SCHEMBL17999730 | 0.83 | SNCA (0.68) | SNCABCHEACHEHPGDNOX1 | |
| SCHEMBL21752052 | 0.83 | SNCA (0.68) | SNCABCHEACHEHPGDNOX1 | |
| SCHEMBL19918109 | 0.81 | SNCA (0.73) | SNCABCHEKDM4EMAPK1MAPT | |
| SCHEMBL29406423 | 0.81 | SNCA (0.73) | SNCABCHEKDM4EMAPK1MAPT | |
| SCHEMBL31425263 | 0.81 | BCHE (0.53) | SNCABCHEACHEHPGDTP53 | |
| SCHEMBL19942820 | 0.81 | BCHE (0.49) | SNCABCHEACHEHPGDTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570622-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2026-03-10 | — | — | US | disclosed |
| US-20230295101-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2023-09-21 | — | — | US | disclosed |
| US-11560360-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2023-01-24 | — | — | US | disclosed |
| US-20220081404-A1 | PHENOTHIAZINE ANALOGUES AS MITOCHONDRIAL THERAPEUTIC AGENTS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11560360-B2 | Therapeutic compounds | CFTR, MC2R, RPS21 | SNCA 1861/4885BCHE 2894/4885ACHE 2498/4885 |
| US-12570622-B2 | Therapeutic compounds | CYP11B1, CYP11B2, NDUFAB1 | SNCA 1570/4885BCHE 2792/4885ACHE 3884/4885 |
| US-20230295101-A1 | THERAPEUTIC COMPOUNDS | CFTR, C1R, FURIN | SNCA 2990/4885BCHE 1829/4885ACHE 2217/4885 |
| US-20220081404-A1 | PHENOTHIAZINE ANALOGUES AS MITOCHONDRIAL THERAPEUTIC AGENTS | GSR, COQ8A, TXNRD2 | SNCA 766/4885BCHE 2853/4885ACHE 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.